Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
Recursion's blood vessel disorder drug meets main goal in mid-stage study
Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a condition that causes blood vessel malformation met the main goal of safety and tolerability in a mid-stage study.
Is Recursion Pharmaceuticals a Warren Buffett Stock?
Recursion Pharmaceuticals lacks any of the long history of consistent performance that Buffett favors. Nonetheless, it aspires to become a business with characteristics he might like.
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma.
Is Recursion Pharmaceuticals Stock a Buy?
Recursion is seeking to revolutionize the way we develop drugs. If it's successful, the biotech will reap immense benefits.
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Chris Gibson - Co-Founder and Chief Executive Officer Najat Khan - Chief R&D and Commercial Officer Dave Hallett - Chief Executive Officer (Interim) and Chief Scientific Officer, Exscientia Conference Call Participants Chris Gibson Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, delighted to be joining you on our L(earnings) today.
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.38 per share a year ago.
Is Recursion Pharmaceuticals a Millionaire-Maker?
Recursion could have three different revenue streams one day. Right now, it only has one but another may soon be within reach.
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why
Recursion Pharmaceuticals (RXRX) closed at $8.19 in the latest trading session, marking a -1.92% move from the prior day.
Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?
Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.
Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know
The consensus price target hints at a 43.7% upside potential for Recursion Pharmaceuticals (RXRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Recursion Pharmaceuticals Stock a Buy?
Recursion Pharmaceuticals wants to disrupt drug development. It's leaning on new information technology and automation methods.
